The hepatitis B virus is responsible for most of the chronic liver disease and liver cancer worldwide. As actual therapeutic strategies have had little success in eradicating the virus from hepatocytes, and as lifelong treatment is often required, new drugs targeting the various phases of the hepatitis B virus (HBV) lifecycle are currently under investigation. In this review, we provide an overview of potential future treatments for HBV
Current antiviral therapies have dramatically improved the long-term outcomes of patients with chron...
Chronic hepatitis B virus (HBV) infection remains an important global burden with an estimated 240 m...
Abstract Background Hepatitis B virus (HBV) chronic infection affects up to 240 million people in th...
The hepatitis B virus is responsible for most of the chronic liver disease and liver cancer worldwid...
Approximately 240 million people worldwide are chronically infected with hepatitis B virus (HBV), wh...
Hepatitis B virus (HBV) infection is a global health threat with 240 million chronic carriers at hig...
Currently approved treatments for hepatitis B virus (HBV) infection include the immunomodulatory age...
Despite the accumulating knowledge, chronic hepatitis B (CHB) and HDV infection represent a global h...
: These authors contributed equally to this work. Abstract: Approximately 240 million people worldwi...
Chronic hepatitis B (CHB) is a highly complicated pathological process in which the disease is initi...
Over 240 million people worldwide are chronically infected with hepatitis B virus (HBV) and although...
Chronic infection with hepatitis B virus (HBV) constitutes a major global public health threat, caus...
Hepatitis B virus (HBV) remains a major public health issue with more than 350 million people chroni...
Hepatitis B is a widespread disease which affects millions of people worldwide. Chronic hepatitis B ...
Since the discovery of the hepatitis B virus (HBV) by Blumberg et al. in 1965, its genome, sequence,...
Current antiviral therapies have dramatically improved the long-term outcomes of patients with chron...
Chronic hepatitis B virus (HBV) infection remains an important global burden with an estimated 240 m...
Abstract Background Hepatitis B virus (HBV) chronic infection affects up to 240 million people in th...
The hepatitis B virus is responsible for most of the chronic liver disease and liver cancer worldwid...
Approximately 240 million people worldwide are chronically infected with hepatitis B virus (HBV), wh...
Hepatitis B virus (HBV) infection is a global health threat with 240 million chronic carriers at hig...
Currently approved treatments for hepatitis B virus (HBV) infection include the immunomodulatory age...
Despite the accumulating knowledge, chronic hepatitis B (CHB) and HDV infection represent a global h...
: These authors contributed equally to this work. Abstract: Approximately 240 million people worldwi...
Chronic hepatitis B (CHB) is a highly complicated pathological process in which the disease is initi...
Over 240 million people worldwide are chronically infected with hepatitis B virus (HBV) and although...
Chronic infection with hepatitis B virus (HBV) constitutes a major global public health threat, caus...
Hepatitis B virus (HBV) remains a major public health issue with more than 350 million people chroni...
Hepatitis B is a widespread disease which affects millions of people worldwide. Chronic hepatitis B ...
Since the discovery of the hepatitis B virus (HBV) by Blumberg et al. in 1965, its genome, sequence,...
Current antiviral therapies have dramatically improved the long-term outcomes of patients with chron...
Chronic hepatitis B virus (HBV) infection remains an important global burden with an estimated 240 m...
Abstract Background Hepatitis B virus (HBV) chronic infection affects up to 240 million people in th...